Novel targets and improved immunotherapeutic techniques with an emphasis on antimycosal drug resistance for the treatment and management of mycosis
- PMID: 39224344
- PMCID: PMC11367498
- DOI: 10.1016/j.heliyon.2024.e35835
Novel targets and improved immunotherapeutic techniques with an emphasis on antimycosal drug resistance for the treatment and management of mycosis
Abstract
Infections due to pathogenic fungi are endemic in particular area with increased morbidity and mortality. More than a thousand people are infected per year and the way of treatment is of high demand having a significant impact on the population health. Medical practitioners confront various troublesome analytic and therapeutical challenges in the administration of immunosuppressed sufferer at high danger of expanding fungal infections. An upgraded antimycosal treatment is fundamental for a fruitful result while treating intrusive mycoses. A collection of antimycosal drugs keeps on developing with their specific antifungal targets including cell membrane, mitochondria, cell wall, and deoxyribonucleic acid (DNA)/ribonucleic acid (RNA) or protein biosynthesis. Some fundamental classes of ordinarily directed medications are the polyenes, amphotericin B, syringomycin, allylamines, honokiol, azoles, flucytosine, echinocandins etc. However, few immunotherapy processes and vaccinations are being developed to mark this need, although one presently can't seem to arrive at the conclusion. In this review article, there has been a trial to give details upgradation about the current immune therapeutic techniques and vaccination strategies against prevention or treatment of mycosis as well as the difficulties related with their turn of events. There has been also a visualization in the mentioned review paper about the various assorted drugs and their specific target analysis along with therapeutic interventions.
Keywords: CAR-T cell therapy; Candidiasis; Ergosterol; Fungal immunotherapy; Recombinant DNA vaccine.
© 2024 The Authors.
Conflict of interest statement
The authors declare that there are no conflicts of interest.
Figures
Similar articles
-
Promising immunotherapeutic targets for treating candidiasis.Front Cell Infect Microbiol. 2024 Feb 9;14:1339501. doi: 10.3389/fcimb.2024.1339501. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 38404288 Free PMC article. Review.
-
[Antifungals cellular targets and mechanisms of resistance].Therapie. 2006 May-Jun;61(3):195-9. doi: 10.2515/therapie:2006048. Therapie. 2006. PMID: 16989119 Review. French.
-
Changing strategies for the management of invasive fungal infections.Pharmacotherapy. 2004 Feb;24(2 Pt 2):4S-28S; quiz 29S-32S. Pharmacotherapy. 2004. PMID: 14992487 Review.
-
Antifungal Combinations against Candida Species: From Bench to Bedside.J Fungi (Basel). 2022 Oct 13;8(10):1077. doi: 10.3390/jof8101077. J Fungi (Basel). 2022. PMID: 36294642 Free PMC article. Review.
-
Antifungal drug resistance mechanisms.Expert Rev Anti Infect Ther. 2009 May;7(4):453-60. doi: 10.1586/eri.09.18. Expert Rev Anti Infect Ther. 2009. PMID: 19400764 Review.
References
-
- McCaffrey S., Black R.A., Nagao M., Sepassi M., Sharma G., Thornton S., Kim Y.H., Braverman J. Measurement of quality of life in patients with mycosis fungoides/Sézary syndrome cutaneous T-cell lymphoma: development of an electronic instrument. J. Med. Internet Res. 2019;21(1) doi: 10.2196/11302. - DOI - PMC - PubMed
-
- Patterson T.F., Thompson G.R., III, Denning D.W., Fishman J.A., Hadley S., Herbrecht R., Kontoyiannis D.P., Marr K.A., Morrison V.A., Nguyen M.H., Segal B.H., Steinbach W.J., Stevens D.A., Walsh T.J.T., Wingard J.R., Young Jo-A.H., Bennett J.E. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America. Clin. Infect. Dis. 2016;63(4):e1–e60. doi: 10.1093/cid/ciw326. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
